Rohrer TR, Abuzzahab J, Backeljauw P, Birkegård AC, Blair J, Dahlgren
J, Júlíusson PB, Ostrow V, Pietropoli A, Polak M, Romano A, Ross J,
Sävendahl L, Miller BS. Long-term effectiveness and safety of
childhood growth hormone treatment in Noonan Syndrome. Horm Res
Paediatr. 2021; Jan 13:1–16.
Noonan JA, Ehmke DA. Associated noncardiac malformations in children
with congenital heart disease. J Pediatr. 1963; 63:468–470.
Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan
syndrome. Lancet 2013; 381:333–342.
Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB. Noonan's
syndrome: abnormalities of the growth hormone/IGF-I axis and the
response to treatment with human biosynthetic growth hormone. Acta
Paediatr Scand. 1991; 80:446–450.
Cotterill AM, McKenna WJ, Brady AF, Sharland M, Elsawi M, Yamada M,
et al. The short-term effects of growth hormone therapy on height
velocity and cardiac ventricular wall thickness in children with
Noonan's syndrome. J Clin Endocrinol Metab. 1996; 81:2291–2297.
De Schepper J, Otten BJ, Francois I, Bourguignon JP, Craen M, Van der
Burgt I, et al. Growth hormone therapy in pre-pubertal children with
Noonan syndrome: first year growth response and comparison with Turner
syndrome. Acta Paediatr. 1997; 86:943–946.
MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, Savage
MO, et al. Growth hormone therapy and growth in children with Noonan's
syndrome: results of 3 years' follow-up. J Clin Endocrinol
Metab. 2001; 86:1953–1956.
Lee PA, Ross J, Germak JA, Gut R. Effect of 4 years of growth hormone
therapy in children with Noonan syndrome in the American Norditropin
Studies: Web-Enabled Research (ANSWER) Program(R) registry. Int J
Pediatr Endocrinol. 2012; 2012:15.
Municchi G, Pasquino AM, Pucarelli I, Cianfarani S, Passeri F. Growth
hormone treatment in Noonan syndrome: report of four cases who reached
final height. Horm Res. 1995; 44:164–167.
Osio D, Dahlgren J, Wikland KA, Westphal O. Improved final height
with long-term growth hormone treatment in Noonan syndrome. Acta
Paediatr. 2005; 94:1232–1237.
Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten
BJ. Long-term GH treatment improves adult height in children with
Noonan syndrome with and without mutations in protein tyrosine
phosphatase, non-receptor-type 11. Eur J Endocrinol. 2008; 159:203–208.
Raaijmakers R, Noordam C, Karagiannis G, Gregory JW, Hertel NT,
Sipila I, et al. Response to growth hormone treatment and final height
in Noonan syndrome in a large cohort of patients in the KIGS
database. J Pediatr Endocrinol Metab. 2008; 21:267–273.
Malaquias AC, Noronha RM, Souza TTO, Homma TK, Funari MFA, Yamamoto
GL, et al. Impact of Growth Hormone Therapy on Adult Height in
Patients with PTPN11 Mutations Related to Noonan Syndrome. Horm Res
Paediatr. 2019; 91:252–61.
Ranke MB, Lindberg A, Carlsson M, Camacho-Hubner C, Rooman R.
Treatment with growth hormone in Noonan syndrome observed during 25
years of KIGS: near adult height and outcome prediction. Horm Res
Paediatr. 2019; 91:46–55